Murdock, E., Jo, Y., Ozay, Z. I., Nandakumar, V., Gebrael, G., Lin, E., Hooper, G., Sayegh, N., Ostrowski, M., Chehade, C. H., Campbell, P., Srivastava, A., Revillo, R., Nussenzveig, R. H., Maughan, B. L., Li, H., Agarwal, N., Swami, U. (2026). Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.442